Physician
Psychiatry
Dr. Robert A. Lasser, MD
|
|
Give Review
Robert A. Lasser works in the field of Psychiatry. He went to Boston University School of Medicine. Boston University School of Medicine has a rank of 30 in research and a 52 in primary care Doctor Robert A. Lasser, MD is a published MD. He published 47 publications, including: 'Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer''s disease.'
Publications
- The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial.
- Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a...
- Adjunctive Lisdexamfetamine Dimesylate Therapy in Adult Outpatients With Predominant Negative Symptoms of Schizophrenia: Open-Label and Randomized-Withdrawal Phases.
- Efficacy and Safety of Lisdexamfetamine Dimesylate in Children with Attention-Deficit/Hyperactivity Disorder and Recent Methylphenidate Use.
- Parent-reported executive function behaviors and clinician ratings of attention-deficit/hyperactivity disorder symptoms in children treated with lisdexamfetamine dimes...
- Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
- Managing ADHD across the lifespan in the primary care setting.
- A New Psychosocial Tool for Gaining Patient Understanding and Acceptance of Long-acting Injectable Antipsychotic Therapy.
- Evaluation of a treatment manual for risperidone long-acting injectable.
- Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness.
- Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation.
- A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.
- Methodological issues in a comparative study of ziprasidone and risperidone.
- Remission in schizophrenia: proposed criteria and rationale for consensus.
- Lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder in adults with a history of depression or history of substance use disorder.
- Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: no alteration of soluble gp130.
- The concepts of remission and recovery in schizophrenia.
- Improving patient outcomes in schizophrenia: achieving remission.
- Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis.
- Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study.
- Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity.
- Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease.
- Physostigmine challenge before and after chronic cholinergic blockade in elderly volunteers.
- Longitudinal stability of CSF tau levels in Alzheimer patients.
- Patient-based and clinician-based support for the remission criteria in schizophrenia.
- Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone.
- Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder.
- Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer''s disease.
- Depression in the elderly: biologic considerations.
- Newer psychotropic medication use in nursing home residents.
- Thyroid hormones in depressive disorders: a reappraisal of clinical utility.
- Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.
- Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of...
- Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
- Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone.
- Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-actin...
- Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications.
- Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia.
- Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder.
- Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia.
- An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
- Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection.
- Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial.
- Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone.
- Measuring remission in schizophrenia: response to Sethuraman et al., 2005.
- Remission in schizophrenia: applying recent consensus criteria to refine the concept.
Schools
Boston University School Of Medicine
Doctors Specialties
- Psychiatry
Accepted Insurances
Education
-
National Institutes of Health Clinical Center -
Boston University School of Medicine
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1295752707 |
| Last Name Of The Provider | LASSER |
| First Name Of The Provider | ROBERT |
| View All |